Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application

Chinese Medical Journal

Volumn 112, Issue 11, 1999, Pages 963-967

  Wang, Zhenyi ^a   Sun, Guanlin ^a   Shen, Zhixiang ^a   Chen, Saijuan ^a   Chen, Zhu ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Differentiation

Indexed keywords

RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BASOPHILIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG CLEARANCE; ERYTHEMA NODOSUM; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERLIPIDEMIA; INTRACRANIAL HYPERTENSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; RECURRENCE RISK; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; REMISSION INDUCTION; SURVIVAL RATE; TRETINOIN;

EID: 0032753565     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sachs L. Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature 1978;274: 535-539.
2. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980;77:2936-2940.
3. Flynn PJ, Miller WJ, Weidorf DJ, et al. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observation. Blood 1983;62:1211-1217.
4. Nilsson B. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1984;57:363-371.
5. Huang ME, Ye YC, Wang ZY. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. Chin J Intern Med 1987;26:330-332.
6. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72: 567-572.
7. Wang ZY, Sun GL, Ye YC, et al. Clinical observation on 90 cases of acute promyelocytic leukemia with all-trans retinoic acid. Chin J Hematol 1990;11:480-481.
8. Chen ZX, Xue YQ, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia. Blood 1991;78:1413-1419.
9. Sun GL, Huang YG, Chang XF, et al. Chinese Cooperative Study Group on the Treatment of APL with ATRA. Clinical study on all-trans retinoic acid in the treatment of 544 patients with APL. Chin J Hematol 1992;13:135-137.
10. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood 1990;76:1704-1709.
11. Tallman MS, Anderson JW, Aschiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-1028.
12. Asou N, Adachi K, Tamura J, et al. The Japan Adult Leukemia Study Group. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia. Comparison with intensive chemotherapy. Cancer Chemother Pharmacol 1997;40:S30-S35.
13. Soignet S, Fleischauer A, Polyak T, et al. All-trans retinoic acid significantly increase 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York Study. Cancer Chemother Pharmacol 1997;40:S25-S29.
14. Fenaux P, LeDeley MC, Castaigne S, et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-3249.
15. Head D, Kopecky KJ, Weick J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:1717-1728.
16. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995;85:1202-1206.
17. Mandelli F, Diverio D, Awisati G, et al. Molecular remission in PML/RAR alpha-positive APL by combined ATRA and idarubicin therapy. Gruppo Italiano-Mallatie Ematologiche Maligne dell' Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997;90:1014-1021.
18. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factor in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16:78-85.
19. Qi XQ, Miao JM, Fan ZW, et al. Studies on clinical pharmacokinetics of all-trans retinoic acid. Chin J Hematol 1994; 15: 70-72.
20. Wang ZY, Chen Zhu, eds. Treatment of tumors by inducing differentiation and apoptosis. Shanghai: Shanghai Publishing House of Science and Technology, 1998:92-117.
21. Degos L, Dombret H, Chomienne C, et al. All-trans retinoic acid aa a differentiation agent in the treatment of acute promyelocytic leukemia. Blood 195;85:2643-2653.
22. Wiley IS and Firkin FC for the Australian Leukaemia Study Group. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995;9:774-778.
23. Deng XM, Wang DB, Fu JF, et al. Hyperleucocytosis in all-trans retinoic acid treated acute promyelocytic leukemia and its management. Chin J Hematol 1995;16:341-343.
24. Sun GL, Ouyang RR, Chen SJ, et al. Shanghai Cooperative Study Group on APL treated with ATRA. Treatment of acute promyelocytic leukemia with all-trans retinoic acid-A five-year experience. Chin Med J 1993;106:743-748.
25. Warrell RP Jr, Maslak P, Eardley A, et al. Treatment of APL with ATRA, an update of the New York experience. Leukemia 1994;8:S33-S37.
26. Jiang B, Wang DB, Shan FX, et al. Post-remission treatment and follow-up in 40 acute promyelocytic leukemia patients. Chin J Hematol 1995;16:247-249.
27. Miller WH, Jakubowski A Jr, Tong WP, et al. 9-cis retinoic acid induces complete remission, but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 1995;85:3021-3027.
28. Tobita T, Takeshita A, Kitamura K, et al. Treatment of a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997;90:967-973.
29. Zhang P, Wang SY, Hu LH, et al. Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chin J Hematol 1996;17:58-60.
30. 3 in the treatment of acute promyelocytic leukemia (APL): (II). clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
31. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
32. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leukemia: arsenic induces NB4 cell apoptosis with down regulation of BCL-2 and modulation of PML-RARA proteins. Blood 1996;88:1052-1061.
33. Chen SJ, Wang ZY, Chen Z. Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells 1995;13:22-31.
34. Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood 1998;91:2631-2633.